We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+38.02%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.72B
AUM Growth
+$398M
Cap. Flow
+$23.1M
Cap. Flow %
1.34%
Top 10 Hldgs %
68.24%
Holding
45
New
–
Increased
23
Reduced
5
Closed
3

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$28.6M
2
SAGE
Sage Therapeutics
SAGE
+$19.7M
3
FOLD
Amicus Therapeutics
FOLD
+$11.3M
4
PRTA icon
Prothena Corp
PRTA
+$7.82M
5
UTHR icon
United Therapeutics
UTHR
+$5.38M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$21.9M
2
MDVN
MEDIVATION, INC.
MDVN
+$16.5M
3
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$15.8M
4
SQNM
SEQUENOM INC NEW
SQNM
+$9.43M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$1.55M

Sector Composition

Rank Sector Weight
1 Healthcare 94.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABMD
1
DELISTED
Abiomed Inc
ABMD
$242M 14.07%
1,884,384
-182,535
-9% -$21.9M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$208M 12.1%
1,763,458
+44,800
+3% +$5.38M
BMRN icon
3
BioMarin Pharmaceuticals
BMRN
$12.4B
$166M 9.62%
1,790,899
+53,500
+3% +$5.04M
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
$137M 7.97%
3,804,088
– –
AMAG
5
DELISTED
AMAG Pharmaceuticals
AMAG
$81.5M 4.74%
3,326,720
+53,500
+2% +$1.34M
INSM icon
6
Insmed
INSM
$28.6B
$73.9M 4.29%
5,091,298
+36,585
+0.7% +$458K
CEMP
7
DELISTED
Cempra, Inc.
CEMP
$68.8M 4%
2,844,483
+56,941
+2% +$1.23M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$68.8M 4%
561,700
+222,300
+65% +$28.6M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$302M
$68.4M 3.97%
4,110,708
-114,900
-3% -$1.55M
WMGI
10
DELISTED
Wright Medical Group Inc
WMGI
$59.9M 3.48%
2,440,493
+32,100
+1% +$739K
PRTA icon
11
Prothena Corp
PRTA
$450M
$56M 3.26%
934,455
+145,837
+18% +$7.82M
ZLTQ
12
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$55.5M 3.22%
1,414,563
+23,484
+2% +$839K
ACAD icon
13
Acadia Pharmaceuticals
ACAD
$5.03B
$47.1M 2.74%
1,481,930
+44,200
+3% +$1.5M
FOLD
14
DELISTED
Amicus Therapeutics
FOLD
$42.1M 2.44%
5,685,388
+1,676,013
+42% +$11.3M
SAGE
15
DELISTED
Sage Therapeutics
SAGE
$41.5M 2.41%
902,051
+484,173
+116% +$19.7M
ARIA
16
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$35.4M 2.06%
2,587,617
+52,500
+2% +$527K
CELG
17
DELISTED
Celgene Corp
CELG
$30.6M 1.78%
292,700
+13,100
+5% +$1.42M
STAA icon
18
STAAR Surgical
STAA
$1.21B
$30.5M 1.77%
3,244,610
+37,400
+1% +$300K
KPTI icon
19
Karyopharm Therapeutics
KPTI
$48M
$30M 1.74%
205,723
-3,573
-2% -$429K
EPZM
20
DELISTED
Epizyme, Inc
EPZM
$27.7M 1.61%
2,814,540
+103,159
+4% +$942K
GILD icon
21
Gilead Sciences
GILD
$165B
$25.2M 1.46%
318,400
– –
SHPG
22
DELISTED
Shire pic
SHPG
$23.9M 1.39%
123,200
+3,900
+3% +$761K
MNTA
23
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$19.3M 1.12%
1,650,876
+21,800
+1% +$256K
ENDP
24
DELISTED
Endo International plc
ENDP
$19M 1.11%
945,330
+22,100
+2% +$439K
RIGL icon
25
Rigel Pharmaceuticals
RIGL
$750M
$19M 1.11%
518,609
-20,044
-4% -$575K
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
GPSPJS
General Pension Society PZU Joint Stock Warsaw, Poland $654M AUM 55.85% 1-Year Est. Return
W
WPWealth Fort Worth, Texas $654M AUM 13.19% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $655M AUM 24.57% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
SCM
Stevens Capital Management Radnor, Pennsylvania $649M AUM 27.37% 1-Year Est. Return

Palo Alto Investors's Q3 2016 Portfolio in Review

As of Q3 2016, Palo Alto Investors held 45 positions worth $1.72B, up 30% from $1.32B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Palo Alto Investors's Q3 2016 filing shows 23 increased, 5 reduced and 3 closed positions. The largest sale was Abiomed Inc, an estimated $21.9M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 91% a quarter earlier.

  • Palo Alto Investors added most to Alexion Pharmaceuticals in Q3 2016, an estimated $28.6M increase.
  • Palo Alto Investors's biggest Q3 2016 reduction was Abiomed Inc, cutting an estimated $21.9M.
  • Palo Alto Investors fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $16.5M.
  • Palo Alto Investors's ten largest holdings make up 68% of its $1.72B portfolio in Q3 2016.
  • Palo Alto Investors opened 0 new positions and closed 3 in Q3 2016.
  • Palo Alto Investors's portfolio value rose 30% quarter-over-quarter to $1.72B.

Based on Palo Alto Investors's 13F filing for Q3 2016, filed 14 Nov 2016.